 |
2007
- December 21, 2007 - Cougar Biotechnology Initiates Phase I Trial for CB3304 (Noscapine)
Read » | PDF »
- December 17, 2007 - Cougar Biotechnology Announces $87 Million Private Placement
Read » | PDF »
- December 4, 2007 - Cougar Biotechnology Announces Move to The NASDAQ Global Market
Read » | PDF »
- November 20, 2007 - Cougar Biotechnology to Present at Lazard Capital Markets Fourth Annual Healthcare Conference
Read » | PDF »
- November 9, 2007 - Cougar Biotechnology Presents Positive CB7630 Phase II Data at Chemotherapy Foundation Symposium
Interim Phase II Results Support Efficacy of CB7630 in Chemotherapy Refractory Prostate Cancer Patients
Read » | PDF »
- October 30, 2007 - Cougar Biotechnology to Present at Upcoming Investor Conferences
Read » | PDF »
- October 25, 2007 - Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Phase I Results Support the Safety and Efficacy of CB7630 When Taken With or Without Food in Castration Resistant Prostate Cancer Patients
Read » | PDF »
- October 12, 2007 - Cougar Biotechnology Presents Positive CB7630 Phase II Data at Prostate Cancer Foundation Scientific Retreat
Interim Phase II Results Confirm Efficacy of CB7630 in Both Chemotherapy Naïve and Chemotherapy Refractory Prostate Cancer Patients
Read » | PDF »
- September 27, 2007 - Cougar Biotechnology Appoints Samuel Saks to Board of Directors
Read » | PDF »
- August 29, 2007 - Cougar Biotechnology to Present at NewsMakers in the Biotech Industry Conference
Read » | PDF »
- July 19, 2007 - Cougar Biotechnology Announces Allowance of IND for CB 3304 (Noscapine)
Read » | PDF »
- July 8, 2007 - Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Read » | PDF »
- July 2, 2007 - Cougar Biotechnology Appoints Tom Malley to Board of Directors
Read » | PDF »
- June 4, 2007 - Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
Read » | PDF »
- May 21, 2007 - Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
Interim Phase II Results Confirm Efficacy of CB7630 in Chemotherapy Naïve Castration Resistant Prostate Cancer Patients
Read » | PDF »
- May 15, 2007 - Cougar Biotechnology Announces Additions to Clinical Research and Development Team
Read » | PDF »
- May 3, 2007 - Cougar Biotechnology Announces $50 Million Private Placement
Read » | PDF »
- April 17, 2007 - Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
Read » | PDF »
- April 5, 2007 - Cougar Biotechnology to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
Read » | PDF »
- March 12, 2007 - Cougar Biotechnology to Present at Cowen and Company's 27th Annual Health Care Conference
Read » | PDF »
- February 23, 2007 - Cougar Biotechnology Announces Presentation of Positive Phase I and
Phase II Data at ASCO Prostate Cancer Symposium
Read » | PDF »
- February 14, 2007 - Cougar Biotechnology Names Richard B. Phillips, Ph.D. Vice President of Regulatory Affairs and Quality Assurance
Read » | PDF »
- February 7, 2007 - Cougar Biotechnology Announces Listing of Common Stock
Read » | PDF »
2006
- December 14, 2006 - Cougar Biotechnology Initiates Phase II trial of CB7630 (Abiraterone Acetate)
Read » | PDF »
- December 8, 2006 - Cougar Biotechnology Presents Positive CB7630 Phase I data at the AACR Innovations in Prostate Cancer Research Conference
Read » | PDF »
- October 8, 2006 - Cougar Biotechnology Announces Positive CB7630 Phase I data Presented at the National Cancer Research Institute Conference Read » | PDF »
- September 27, 2006 - Cougar Biotechnology Announces CB7630 Phase I data to be presented at National Cancer Research Institute Conference Read » | PDF »
- September 11, 2006 - Cougar Biotechnology Appoints Dr. Russell Ellison to Board of Directors Read » | PDF »
- July 11, 2006 - Cougar Biotechnology Announces Initiation of Phase I trial for CB7630 (Abiraterone Acetate) Read » | PDF »
- June 14, 2006 - Cougar Biotechnology Appoints Michael Richman to Board of Directors Read » | PDF »
- May 9, 2006 - Cougar Biotechnology Announces Presentation at Rodman & Renshaw 3rd Annual Global Healthcare Conference Read » | PDF »
- April 10, 2006 - Cougar Biotechnology Completes Merger and Closes $47.5 Million Private Placement Read » | PDF »
- March 23, 2006 - Cougar Biotechnology to Present at SoCalBio Investor Conference Read » | PDF »
- March 3, 2006 - Cougar Biotechnology to Present at Cowen & Co. 26th Annual Health Care Conference Read » | PDF »
- February 2, 2006 - Cougar Biotechnology Announces Approval of IND for Abiraterone Acetate Read » | PDF »
2005
- December 14, 2005 - Cougar Biotechnology Announces Initiation of Phase I/II trial for CB7630 (Abiraterone Acetate) Read » | PDF »
- December 13, 2005 - Cougar Biotechnology Announces Presentation of Positive Preclinical Data for CB3304 (Noscapine) in Non-Hodgkin's Lymphoma and Multiple Myeloma Read » | PDF »
- December 12, 2005 - Cougar Biotechnology Announces Positive Interim Results from Phase I trial for CB3304 (Noscapine) in non-Hodgkin's Lymphoma Read » | PDF »
- November 2, 2005 - Cougar Biotechnology Announces Presentation at Rodman & Renshaw Techvest 7th Annual Healthcare Conference Read » | PDF »
- October 5, 2005 - Cougar Biotechnology Announces Acceptance of CTA for Abiraterone Acetate Read » | PDF »
- June 28, 2005 - Cougar Biotechnology Licenses Rights to Seocalcitol from LEO Pharma Read » | PDF »
- February 21, 2005 - Cougar Biotechnology Presents CB7630 Phase I Clinical Data at the 2005 Prostate Cancer Symposium Read » | PDF »
2004
- November 9, 2004 - Cougar Biotechnology Appoints Vice President of Clinical Research and Development Read » | PDF »
- October 25, 2004 - Cougar Biotechnology Presents CB7630 Phase I Data at Prostate Cancer Foundation Scientific Retreat Read » | PDF »
- September 9, 2004 - Cougar Biotechnology Appoints Vice President of Finance Read » | PDF »
- June 15, 2004 - Cougar Biotechnology Licenses Rights to Emory University's Noscapine Patent Portfolio Read » | PDF »
- April 20, 2004 - BTG Licenses New Prostate Cancer Drug to Cougar Biotechnology Read » | PDF »
| | |
Cougar Biotechnology, Inc.
10990 Wilshire Blvd, Suite 1200
Los Angeles, CA 90024
(310) 943-8040 Main
(310) 943-8059 Fax |
